BACKGROUND: New anti-IL-5 antibodies, mepolizumab and benralizumab, have recently been approved for severe asthma, sharing the same inclusion criteria. OBJECTIVE: To contribute on biomarkers research leading to the personalized choice, we investigated L-selectin, Krebs von den Lungen (KL-6), and lymphocyte subsets as bioindicators of airway hyper-responsiveness and remodeling. MATERIALS AND METHODS: A cohort of 28 patients affected by severe eosinophilic asthma were treated with anti-IL-5 drugs. According to clinical parameters, patients were subdivided into early and partial responders. Lymphocytes subsets were analyzed through flow cytometry, while KL-6 and sL-selectin were analyzed on serum samples. Clinical, functional, and immunological data at baseline (T0), after 1 month (T1), and 6 months of therapy were collected in a database. RESULTS: All treated patients showed an increase in the percentage of forced expiratory volume in the first second (FEV1) and FEV1/forced vital capacity ratio and a decrease of peripheral eosinophils for both drugs after 1 month of treatment. Mepolizumab-treated patients also showed decreased CD8+ and NKT-like cell percentages and a significant increase in sL-selectin concentrations between T0 and T1. Stratifying the cohort of our patients in early and partial responders at T0, they showed a reduction of peripheral eosinophils, sL-selectin and KL-6, while no differences were found at T0 between early and partial responders patients treated with benralizumab. CONCLUSIONS: This real-life study provides new insights for the personalized approach to severe asthma therapy. Although preliminary, the results indicate that besides eosinophils, KL-6 and sL-selectin are useful as biomarkers of early response that can also involve in the pathogenesis of severe asthma.
BACKGROUND: New anti-IL-5 antibodies, mepolizumab and benralizumab, have recently been approved for severe asthma, sharing the same inclusion criteria. OBJECTIVE: To contribute on biomarkers research leading to the personalized choice, we investigated L-selectin, Krebs von den Lungen (KL-6), and lymphocyte subsets as bioindicators of airway hyper-responsiveness and remodeling. MATERIALS AND METHODS: A cohort of 28 patients affected by severe eosinophilic asthma were treated with anti-IL-5 drugs. According to clinical parameters, patients were subdivided into early and partial responders. Lymphocytes subsets were analyzed through flow cytometry, while KL-6 and sL-selectin were analyzed on serum samples. Clinical, functional, and immunological data at baseline (T0), after 1 month (T1), and 6 months of therapy were collected in a database. RESULTS: All treated patients showed an increase in the percentage of forced expiratory volume in the first second (FEV1) and FEV1/forced vital capacity ratio and a decrease of peripheral eosinophils for both drugs after 1 month of treatment. Mepolizumab-treated patients also showed decreased CD8+ and NKT-like cell percentages and a significant increase in sL-selectin concentrations between T0 and T1. Stratifying the cohort of our patients in early and partial responders at T0, they showed a reduction of peripheral eosinophils, sL-selectin and KL-6, while no differences were found at T0 between early and partial responders patients treated with benralizumab. CONCLUSIONS: This real-life study provides new insights for the personalized approach to severe asthma therapy. Although preliminary, the results indicate that besides eosinophils, KL-6 and sL-selectin are useful as biomarkers of early response that can also involve in the pathogenesis of severe asthma.
Authors: Lorenza Vantaggiato; Paolo Cameli; Laura Bergantini; Miriana d'Alessandro; Enxhi Shaba; Alfonso Carleo; Fabrizio Di Giuseppe; Stefania Angelucci; Guido Sebastiani; Francesco Dotta; Luca Bini; Elena Bargagli; Claudia Landi Journal: Biomedicines Date: 2022-03-24
Authors: José A Cañas; Marcela Valverde-Monge; José M Rodrigo-Muñoz; Beatriz Sastre; Marta Gil-Martínez; Raquel García-Latorre; Manuel J Rial; Aida Gómez-Cardeñosa; Mar Fernández-Nieto; Erwin J Pinillos-Robles; María J Rodríguez-Nieto; Nicolás González-Mangado; Joaquín Sastre; Victoria Del Pozo Journal: J Pers Med Date: 2021-01-28
Authors: Laura Bergantini; Miriana d'Alessandro; Paolo Cameli; Dalila Cavallaro; Sara Gangi; Behar Cekorja; Piersante Sestini; Elena Bargagli Journal: Cells Date: 2021-11-15 Impact factor: 6.600
Authors: Moritz Z Kayser; Nora Drick; Katrin Milger; Jan Fuge; Nikolaus Kneidinger; Stephanie Korn; Roland Buhl; Jürgen Behr; Tobias Welte; Hendrik Suhling Journal: J Asthma Allergy Date: 2021-07-12